Effects of obesity on lower urinary tract symptoms in Korean BPH patients by 김장환 et al.
663
http://www.asiaandro.com;  aja@sibs.ac.cn  |  Asian Journal of Andrology
npg
Effects of obesity on lower urinary tract symptoms in Korean 
BPH patients
Seung Hwan Lee1, Joon Chul Kim2, Ji-Youl Lee2, Jang Hwan Kim1, Cheol Young Oh3, Seung Wook Lee4,
Se Jeong Yoo1, Byung Ha Chung1
1Department of Urology, Yonsei University Health System, Seoul 135-720, Korea 
2Department of Urology, The Catholic University of Korea, Seoul 137-701, Korea
3Department of Urology, Hallym University, Chuncheon 200-704, Korea 
4Department of Urology, Eulji Medical Center, Eulji University, Seoul 139-230, Korea
Correspondence to: Dr Byung Ha Chung, Department of Urology, 
Yonsei University Health System, Gangnam Severance Hospital, 
Yongdong, PO Box 1217, Seoul 135-720, Korea.   
Fax: +82-2-3462-8887               E-mail: chung646@yuhs.ac
Received: 30 June 2009             Revised: 3 August 2009
Accepted: 20 August 2009    Published online: 21 September 2009
Original Article
Asian Journal of Andrology (2009) 11: 663–668
© 2009 AJA, SIMM & SJTU  All rights reserved 1008-682X/09 $ 32.00
www.nature.com/aja
Abstract
We analyzed the effects of obesity on lower urinary tract symptoms (LUTSs) in Korean benign prostatic 
hyperplasia (BPH) patients.  This is a multicenter, cross-sectional, prospective study conducted in four centers in 
Korea.  A total of 602 men with LUTSs secondary to BPH were included.  BPH/LUTSs cases were men aged 
≥ 40 years with international prostate symptom scores (IPSS) ≥ 8 points.  Height, weight and waist circumference 
were measured.  Among the 602 patients, 156 patients had a waist circumference above 90 cm, representing central 
obesity, and 215 patients had a body mass index above 25 kg m-2.  Waist circumference was positively correlated 
with prostate volume (P = 0.034).  Men with waist circumference > 90 cm experienced a 1.36-fold increased risk 
of severe LUTSs (95% CI 0.82–2.41) compared with men with waist circumference ≤ 90 cm.  Prostate volume 
was positively correlated with urgency and nocturia in men with central obesity.  In this population of Korean men 
diagnosed with BPH, central obesity rather than overall obesity seems to be the more important predictor of LUTSs 
correlated with BPH.
Asian Journal of Andrology (2009) 11: 663–668.  doi: 10.1038/aja.2009.62; published online 21 September 2009.
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1    Introduction
Lower urinary tract symptoms (LUTSs), often 
the result of benign prostatic hyperplasia (BPH), 
are common among older men and have a negative 
impact on quality of life (QoL).  Most men after 
the fifth decade experience symptoms of BPH [1]. 
Despite its frequency and its impact on quality of life, 
the pathophysiology of BPH is unclear and there is 
controversy about the risk factors that contribute to 
the development and aggravation of BPH [2].  Recent 
studies concerning the pathophysiology of BPH have 
suggested that in addition to the conventional risk 
factors, such as age, family history and androgen 
activity, newly identified risk factors, such as smoking, 
diet and obesity, may have a major role in the 
development of BPH [2, 3].
LUTSs and obesity are common in older men and 
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may greatly affect their QoL.  Positive associations 
between anthropometric measures of obesity and 
LUTSs were observed in one cohort study, but not 
in another [4, 5].  In addition, on the basis of the 
observation in a clinic-based study of 158 patients 
that an enlarged prostate is more often diagnosed in 
men who have components of a metabolic syndrome, 
such as insulin-dependent diabetes mellitus (DM), 
hypertension requiring treatment, low high-density 
lipoprotein–cholesterol levels, high fasting insulin 
levels and obesity, Hammarsten et al. [6]suggested 
that the development of an enlarged prostate might be 
the result of perturbations in insulin control and other 
aspects of the metabolic syndrome.
The Korean National Health and Nutrition Surveys 
reported an increase in prevalence of obesity in South 
Korea from 1995 to 2001, and an age-related increase 
in prevalence of obesity in Korean adults, in 2001 [7]. 
The prevalence of clinical BPH was reported to be from 
10.6% to 31% in men over 50 years of age, with an age-
related increase seen in South Korea [8, 9].  However, 
there is insufficient data on risk factors for prostatic 
hyperplasia, especially the role of obesity in Korean 
men.  In this cross-sectional study, we investigated the 
relationship of obesity with clinical markers of LUTSs 
in men aged 40 years or more among BPH/LUTS 
patients.
2    Materials and methods
2.1  Study design
This was a multicenter, prospective, cross-sectional 
study conducted in four urology centers in Korea 
from July 2007 to May 2008 through a questionnaire 
survey and laboratory findings at first visit.  Before 
initiating this study, approval was granted from the 
local institutional review board, and patients provided 
informed consent.
Eligible patients with BPH/LUTSs attending a 
urology clinic for the first time were enrolled.  There 
were no preinclusion or washout periods.  Only one visit 
was planned.  The symptoms of BPH were collected 
through the routine evaluation of BPH using transrectal 
ultrasound of the prostate, uroflowmetry, International 
Prostate Symptom Score (IPSS), urine analysis and 
prostate-specific antigen (PSA) determinations.  Height, 
weight and waist circumference were measured in all 
enrolled patients.  At the initial visit, the following 
variables were also recorded: the patient’s demographic 
data (patient’s initials, age), vital signs (blood pressure, 
pulse), reasons for consultation, duration of symptoms, 
medical history of hypertension or DM, medical 
treatment prescribed (if any) and dosage prescribed. 
The body mass index (BMI) of each patient was 
calculated as the body weight in kilograms divided by 
the square of the height in meters.
2.2  Patients
In total, 602 BPH patients with LUTSs (IPSS 
≥ 8 points) and aged ≥ 40 yrs were included in this 
prospective study.  The exclusion criteria of this study 
included the use of medications affecting prostate 
growth and erectile function such as antiandrogens 
and 5-a-reductase inhibitors.  Patients were also 
excluded from this trial if they had neurogenic 
bladder dysfunction, confirmed prostate cancer, acute 
or chronic urinary retention status, acute or chronic 
prostatitis within the previous 3 months, serum PSA 
levels in excess of 10 ng mL-1, a history of recurrent 
urinary tract infection or bladder stones and previous 
TURP (transurethral resection of the prostate) or other 
surgical intervention related to BPH.  The subjects were 
divided into three groups according to BMI: normal 
(< 22.9 kg m-2), overweight (23–24.9 kg m-2) and 
obese (≥ 25 kg m-2).  They were also categorized into 
two groups by waist circumference: normal waist (≤ 
90 cm) and central obesity (> 90 cm).  Classification of 
the subgroups was based on the Asia–Pacific obesity 
criteria [10].
2.3  Statistical analysis
All analyses were conducted with SAS statistical 
software, version 8.2 (SAS Institute, Cary, NC, USA). 
After performing a covariate analysis of variance for 
adjusting for age, the significance of differences in 
prostate volume, PSA concentration, IPSS and Qmax 
among the groups based on BMI was examined using 
ANOVA (analysis of variance) with Scheffe’s post hoc 
test and among groups based on waist circumference 
using unpaired t-test.  The χ2-test was used to determine 
the statistical significance of differences in DM and 
hypertension between groups.  As the data for PSA 
concentration, prostate volume, residual volume and 
Qmax were not normally distributed, we examined the 
data after logarithmic transformation.  After adjusting 
for age, we used linear regression to examine the 
association between metabolic components and prostate 
volume.  Multivariate logistic regression analyses was 
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used for risk factors of severe LUTSs, adjusting for age, 
prostate volume and PSA.  P < 0.05 was considered to 
be statistically significant.
3    Results
The overall mean prostate volume was 33.1 ± 7.6 cm3 
(range 20.0–98.0 cm3).  Among the 602 patients, 156 
patients had a waist circumference above 90 cm, 
representing central obesity, and 215 patients had a 
BMI above 25 kg m-2.  Mean prostate volume was 31.6 
± 11.4 and 34.7 ± 14.2 cm3 in the ≤ 90 and > 90 cm waist 
groups, respectively, and 31.4 ± 11.0, 32.5 ± 11.5 and 
33.4 ± 13.8 cm3 in the normal, overweight and obese 
groups, respectively.  After adjusting for age, men with 
an obese waist circumference had a greater median 
prostate volume (P = 0.021) (Table 1).  Moreover, in 
the regression analyses after adjusting for age, waist 
circumference was positively correlated with prostate 
volume (P = 0.034) (Table 2).
An obese waist circumference was statistically 
associated with DM and hypertension; however, BMI 
was correlated only with hypertension (Table 1).  Men 
with waist circumference > 90 cm had significantly 
lower PSA levels compared with men with waist 
circumference ≤ 90 cm (P = 0.04).
The odds ratios of severe LUTSs (IPSS ≥ 19) in 
relation to BMI, waist circumference, presence of 
diabetes and hypertension are summarized in Table 3. 
Men with waist circumference > 90 cm experienced a 
Table 1.  Age-adjusted demographic characteristics of the study subjects according to waist circumference and BMI.
  Waist circumference Waist circumference  BMI < 22.9 kg m-2 BMI 23–24.9 kg m-2      BMI  ≥ 25 kg m-2 
             ≤ 90 cm           > 90 cm         normal       overweight        obese 
 Number       446       156       209       178       215
 Prostate volume (cm3) 31.6 ± 11.4 34.7 ± 14.2* 31.4 ± 11.0 32.5 ± 11.5 33.4 ± 13.8
 PSA (ng mL-1) 1.96 ± 1.94 1.73 ± 1.51* 1.61 ± 1.20 1.79 ± 1.31 1.82 ± 1.32
 IPSS (total score) 16.8 ± 6.9 17.4 ± 6.3 17.2 ± 7.6 16.7 ± 6.2 16.9 ± 7.0
 Qmax (mL s
-1) 16.7 ± 8.0 12.1 ± 4.9 21.7 ± 8.5 11.8 ± 6.4 12.8 ± 9.5
 DM (%)     
   Yes      15.7       26.3D=       18.2       16.3       20.5
   No      84.3       73.7       81.8       83.7       79.5
 HTN (%)     
   Yes      33.0       50.0D=       29.2D=       35.4D=       46.5D=
   No      67.0       50.0       70.8       64.6       53.5
Abbreviations: BMI, body mass index; PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; DM, diabetes 
mellitus.
The values for prostate volume, PSA, IPSS, QoL and Qmax are expressed as means ± SD.  
*P < 0.05 by unpaired t-test, compaired with 
the group of waist circumference ≤ 90 cm;  D=P < 0.05 among three groups by χ 2-test.
Table 2.  Linear regression analyses evaluating factors correlated 
with prostate volume.
  Coefficient P-value
 BMI (kg m-2)a 0.120 0.687
 Waist circumference (cm)a 0.277 0.034
 DMb 0.736 0.597
 Hypertensionb 0.201 0.861
aComponent is continuous variable;  
bComponent is absent or present.
Table 3.  Odds ratio of severe LUTSs according to metabolic 
markers.
  P-value ORa (95% CI)
BMI (kg m-2)  
   < 22.9 (normal)    [1] (Reference)
   23 – 24.9 (overweight) 0.15 1.17 (0.65 – 2.03)
   ≥ 25 (obese) 0.09 1.19 (0.62 – 2.21)
Waist circumference (cm)  
   ≤ 90     [1] (Reference)
   > 90  0.04 1.36 (0.82 – 2.41)
Abbreviations: CI, confidence interval; LUTS, lower urinary 
tract symptom. 
aOdds ratio adjusted for age, prostate volume and PSA.Severe 
LUTS is defined as IPSS ≥ 19.
1.36-fold increased risk of severe LUTSs (95% CI 0.82 
–2.41) compared with men with waist circumference 
≤ 90 cm.  Men with diabetes experienced a 1.53-fold 
increased risk of severe LUTSs (95% CI 0.60–2.33) 
compared with men without diabetes.
Table 4 indicates that the larger the prostate volume, 
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the higher the BPH/LUTS severity scores, especially in 
men with waist circumference > 90 cm (P = 0.02).  In 
these patients, prostate volume was positively correlated 
with urgency and nocturia among irritative symptoms 
and with incomplete emptying among obstructive 
symptoms after adjustment for age (P < 0.05).
 
4    Discussion
Our data showed that prostate volume was positively 
correlated with central obesity, as represented by waist 
circumference, but not with BMI, representing overall 
obesity.  However, it is known that obesity and BMI are 
significantly associated with the risk of BPH and with 
prostate volume [11].  In an American case–control 
study of black men, Sarma et al. [12] reported that 
BMI was directly associated with prostate volume. 
The positive associations described between BMI and 
prostate volume, however, have not been consistently 
observed across studies.  There was no association 
between BMI and BPH in a Greek study [13].  In a 
Chinese study, there was no relationship with BMI, 
but a direct association was observed with the waist/
hip ratio [14].  In another study, body surface area 
positively correlated with prostate volume, whereas 
BMI did not [15].  Lee et al. [16] found that centrally 
obese men had lower testosterone concentrations 
and greater prostate volume.  Obesity raises estrogen 
levels, as well as free and total estradiol concentrations 
while lowering free and total testosterone and serum 
globulin-binding protein levels [17].  Greater estrogen 
levels in the environment of age-induced and obesity-
induced lower testosterone levels may affect prostate 
cell growth.  Especially, abdominal obesity increases 
the estrogen to androgen ratio and may increase 
sympathetic nervous activity, both known to influence 
the development of BPH and the severity of LUTSs [4, 
18].  One more pathway that explains the increased risk 
for BPH in centrally obese men is the linkage of the 
quality of venous drainage to BPH [19].  Gat et al. [19] 
observed that BPH developed because of an impairment 
of the testicular venous drainage system in the erect 
posture.  They found that in BPH patients, the one-way 
valves in the vertically oriented internal spermatic veins 
are destroyed (clinically manifested as varicocele), 
causing elevated hydrostatic pressure, some sixfold 
greater than normal, in the venous drainage of the male 
reproductive system.  Furthermore, in the centrally 
obese men, big abdominal mass just above the testicular 
venous system may affect the prostate.  However, in the 
current study, we did not have data about the testicular 
drainage system.  The causal relation between the 
central obesity and the prostate volume requires further 
study.
In our study, serum PSA level was associated with 
waist circumference but not with BMI.  Serum PSA 
levels may be affected by many factors, such as, age, 
prostate volume and obesity.  Recently, several studies 
have found a greater BMI to be linked with lower PSA 
levels [18, 20–21].  In contrast, Ochiai et al. [22] reported 
that the anthropometric parameters were not directly 
associated with the PSA levels.  Even though obesity is 
Table 4.  Partial Pearson correlation analyses. Distribution of individual symptoms according to waist circumferences and BMI.
                                                                Prostate volume
          Waist circumferences (cm)                                  BMI (kg m-2)
        ≤ 90    > 90       < 22.9     23 – 24.9       ≥ 25 
IPSS (total)    0.07961 0.24726D=   – 0.03453     0.19973D=    0.06521
Obstructive symptoms    
   Incomplete emptying    0.23202D= 0.32384D=      0.02844     0.05966 – 0.02948
   Straining – 0.01139 0.01932   – 0.04012     0.04327    0.03869
   Weak stream    0.00384 0.07499   – 0.02941     0.03082    0.01203
   Intermittency    0.07556 0.11742      0.05143  – 0.00268    0.09955
Irritative symptoms    
   Urgency    0.08094 0.28132D=   – 0.01035     0.20325D=    0.03229
   Frequency    0.10032 0.13810      0.03812     0.12034    0.10753
   Nocturia    0.12486 0.20127D=      0.08133     0.11019    0.06522
Abbreviations: BMI, body mass index; IPSS, International Prostate Symptom Score.   All values shown are partial correlation 
coefficient adjusted by age.
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a major anthropometric factor in metabolic syndrome, 
complex interrelationships exist among individual 
anthropometric parameters partly because of their 
associations with obesity.  Kristal et al. [21]reported 
that PSA levels were ~0.2–0.4 ng ml-1 lower among 
individuals who were obese but otherwise healthy as 
compared with non-obese; however, unfortunately, the 
magnitude of the correlation between serum PSA levels 
and the presence of each metabolic component still 
remains unclear.  Given that the prevalence of obesity 
and metabolic syndrome are increasing worldwide and 
that the world population is aging, the effect of obesity 
and related anthropometric factors on altered PSA levels 
warrant further clarification.  In the Olmsted county 
study, Burke et al. [23] observed that diabetic men had 
a significantly greater AUASI (the American Urological 
Association Symptom Index) score and a lower 
peak urinary flow rate compared with those without 
diabetes.  However, no significant difference was found 
in changes in prostatic volume, suggesting that the 
presence of diabetes may be more closely associated 
with the dynamic components of lower urinary tract 
function than with BPH progression.  Another report 
showed that the incidence of nocturia increased with 
increasing BMI [24].  In our study, we observed that 
the irritative symptoms, such as nocturia and urgency, 
increased with the increases of prostate volume in men 
with waist circumference > 90 cm.  The mechanisms 
underlying the association between obesity and nocturia 
are as yet unknown.  Obesity could cause nocturia by 
increased urine production or by increased voiding 
frequency.  Obese men may have increased nocturnal 
production of urine as a result of increased fluid intake 
before bedtime, or centrally obese men can have an 
increased intra abdominal pressure, and therefore, cause 
nocturia.  Obesity may also increase the risk of nocturia 
by causing BPH [25].
Limitations affecting our current findings must 
be considered.  First, our study is cross-sectional, a 
method that might not allow definitive conclusions 
about causal links between the severity of LUTSs and 
the investigated variables.  Second, the patients in this 
study had IPSS ≥ 8 points.  Exclusion of men with 
IPSS < 8 may have increased the sensitivity to detect 
associations of obesity with LUTSs.  Third, our study 
was limited by relying on the self-reported diagnosis of 
hypertension or DM.  Therefore, we could not assess 
exact duration of concomitant diseases as well as 
medications taken for each subject because of lack of 
relevant information.  Finally, our study did not include 
all demographic variables.  As other sociodemographic 
and health status variables, such as marital status, 
socioeconomic variables and work situation, might 
affect urinary symptoms, additional studies including 
these variables are needed.
In conclusion, this study provides evidence that 
central obesity rather than overall obesity seems to be 
the more important predictor of LUTSs correlated with 
BPH.  
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